Table 2.
Reasons for and patterns of HIV preexposure prophylaxis discontinuation events
| Reasons for discontinuation | First discontinuation (N = 239) n (%) | Second discontinuation (N = 51) n (%) | Third discontinuation (N = 10) n (%) | Fourth discontinuation (N = 2) n (%) | Total discontinuations (N = 302) n (%) |
|---|---|---|---|---|---|
| Decrease in HIV risk perception | 84 (35.2) | 13 (25.5) | 1 (10.0) | 1 (50.0) | 99 (32.8) |
| Non‐adherence to care plan a | 34 (14.2) | 11 (21.6) | 2 (20.0) | 1 (50.0) | 48 (15.9) |
| Not documented | 27 (11.3) | 12 (23.5) | 3 (30.0) | — | 42 (13.9) |
| Insurance barrier | 30 (12.6) | 6 (11.8) | 1 (10.0) | — | 37 (12.3) |
| Medication intolerance | 14 (5.9) | 3 (5.9) | — | — | 17 (5.6) |
| Loss to follow‐up | 13 (5.4) | — | 1 (10.0) | — | 14 (4.6) |
| Other | 12 (5.0) | 3 (5.9) | — | — | 15 (5.0) |
| Medication related toxicities | 9 (3.8) | — | — | — | 9 (3.0) |
| Financial barrier | 7 (2.9) | — | — | — | 7 (2.3) |
| Patient preferenceb | 6 (2.5) | 3 (5.9) | 1 (10.0) | — | 10 (3.3) |
| HIV seroconversionc | 2 (0.8) | — | — | — | 2 (0.7) |
| Transfer of care with intent to discontinued | 1 (0.4) | — | 1 (10.0) | — | 2 (0.7) |
aIncludes non‐adherence to clinical visits, laboratory monitoring and/or medications, or using medications other than as prescribed. bIncludes expressed preference to discontinue PrEP and “experiencing stigma from romantic partners, sexual partners, and/or peers.” cOf the seven seroconversions in the overall cohort, four patients discontinued PrEP prior to seroconversion and their discontinuation events were attributed to other causes, and one patient acquired HIV prior to being prescribed PrEP and was excluded from analyses. dBoth of these patients were moving to a country where PrEP was not available but indicated interest in continuing PrEP, if it had been available.